Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Derma Sciences and Source Medical sign Canadian distribution deal
The five-year agreement begins on June 1 and provides for strong revenue growth for Derma Science, as well as incentives to Source Medical. In addition to distribution fees
The five-year agreement begins on June 1 and provides for strong revenue growth for Derma Science, as well as incentives to Source Medical. In addition to distribution fees
The data show that the vaccine induces an immune response potentially capable of eradicating cells infected by highly divergent influenza viruses. It also has the potential to augment
The lost contract was worth up to $70 million a year, according to The Guardian, but AstraZeneca is said to have taken the news well, remaining confident about
Uracyst is formulated to treat interstitial cystitis (IC), an inflammatory disease of the urinary wall, the most common symptom of which is the need to urgently and frequently
Building on leads generated from Southern Research’s proprietary compound repository, scientists from both companies will interact closely as a drug discovery team in a lead expansion and optimization
Viragen recently reported that the anti-CD55 antibody, known as VG102, was able to enhance the action of Genentech and Biogen Idec’s Rituxan (rituximab), resulting in the significant increase
The study compared Aurexis plus antibiotic therapy to antibiotic therapy alone. Favorable results were observed in the primary composite endpoint of mortality, relapse rate and infection-related complications, and
Under the new agreement, Novavax will manufacture Estrasorb, a topical emulsion for estrogen therapy, and Cardinal Health will be responsible for the fill-finish operation that prepares Estrasorb in
Poorly healing wounds, in part due to impaired circulation, are often a major complication of diabetes and can lead to severe complications if left untreated. The research for
NF-kB Decoy was shown to not only reduce recruitment and proliferation of pro-inflammatory cells but also to induce apoptosis, or cell death, of cells relating to inflammation. NF-kB